Novartis Digital Strategy Dampens COVID-19 Impact
Stockpiling Brings $400m Q1 Sales Boost
The Swiss major says operations have not faced significant disruptions from the coronavirus pandemic but recruitment of patients for new trials, including a high-profile trial of inclisiran, have been impacted.
